Drug

D1328 | Mersalyl

Molecular Formula C13H18HgNO6
Molecular Weight 484.88
Structure
State solid
Clearance The hepatobiliary excretion of mersayl was studied in the isolated perfused rat liver and in isolated rat liver plasma membrane vesicles. In the isolated perfused liver, mersalyl was found to be immediately absorbed by the perfusion medium and concentratively excreted into bile. Uptake is characterized by saturation kinetics (S)0.5 = 20 microM, Vmax = 117 nmoles/min/g liver, cooperatively of mersalyl binding sites, stimulation by extracellular sodium and temperature dependence. Uptake of mersalyl into basolateral membrane vesicles also demonstrates characteristics of a carrier-mediated transport, dependence on extravesicular sodium, cooperativity of mersalyl binding sites, temperature dependence and trans-stimulation by intravesicular non-radioactive mersalyl. Uptake was found to be inhibited by alpha-naphthylacetic acid and mercapto group reagents, suggesting involvement of mercapto groups on the carrier and a binding site for carboxylic anions. Data from the isolated perfused liver and from isolated basolateral vesicles suggest that mersalyl uptake into the liver is carrier mediated. Uptake mechanism and driving forces appear analogous to those for the uptake of chemically related compounds such as taurocholic acid. It is, therefore, speculated that mersalyl may be transported by carrier molecules which accept various chemically unrelated compounds [L1584].
Route of elimination Organic mercury is metabolized into inorganic mercury, which is eventually excreted in the urine and feces [L1582].
Description Thiol group reagents

C

C03BC01 Mersalyl


[C03BC] Mercurial diuretics


[C03B] LOW-CEILING DIURETICS, EXCL. THIAZIDES


[C03] DIURETICS


[C] Cardiovascular system


Toxicity Dose Time Species Model Method Action Positive criterion Reference
PROTON CONDUCTIVITY 130 μM bovine heart MF0, proton conductivity affect 70% inhibition 170

Target Dose Time Species Model Method Action Positive criterion Reference
Fo subunits 130 μM bovine heart MF0, proton conductivity inhibitor 70% inhibition 170
Phosphate carrier protein, mitochondrial inhibitor 230

Pictogram Signal Statements Precautionary Statement Codes
Danger

Aggregated GHS information provided by 38 companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


H300 (100%): Fatal if swallowed [Danger Acute toxicity, oral]


H310 (100%): Fatal in contact with skin [Danger Acute toxicity, dermal]


H330 (100%): Fatal if inhaled [Danger Acute toxicity, inhalation]


H373 (100%): Causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]


H400 (100%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]


H410 (100%): Very toxic to aquatic life with long lasting effects [Warning Hazardous to the aquatic environment, long-term hazard]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


P260, P262, P264, P270, P271, P273, P280, P284, P301+P310, P302+P350, P304+P340, P310, P314, P320, P321, P322, P330, P361, P363, P391, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)


  • (3-(2-(carboxymethoxy)benzamido)-2-methoxypropyl)(hydroxy)mercury 486-67-9 ACM486679
    API0003303 C-33804 C11336
    CAS-486-67-9 CHEBI:6771 DB09338
    DSSTox_CID_26902 DSSTox_GSID_46902 DSSTox_RID_82001
    DTXSID3046902 GTPL5331 Mercurate(1-), [3-[[2-(carboxylatomethoxy)benzoyl]amino]-2-methoxypropyl]hydroxy-, hydrogen
    Mersal Mersalyl Mersalyl acid
    Mersalyl acid, analytical standard NCGC00181320-01 Q424871
    SCHEMBL993248 Tox21_112788

    DrugBank DB09338
    CAS Number 486-67-9
    PubChem Compound 443130